KT&G (033780) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
24 Jun, 2026Executive summary
Achieved record first-half revenue exceeding KRW 3 trillion, driven by strong global cigarette (CC) growth and higher real estate earnings.
Operating income for H1 2025 reached KRW 635.4 billion, up from KRW 558.6 billion in H1 2024.
Net income attributable to owners was KRW 398.9 billion, with EPS at KRW 3,698.
Board approved an interim dividend increase to KRW 1,401 and a KRW 300 billion share buyback and cancellation, progressing 53% of the KRW 1.3 trillion buyback plan.
Focus remains on core business, global competitiveness, and quality-centered profit growth amid market uncertainties.
Financial highlights
Q2 consolidated revenue rose 8.7% year-over-year to KRW 1.5479 trillion, with operating profit up 8.6% to KRW 349.8 billion.
Net income declined 54.1% to KRW 143.5 billion due to lower currency-related non-operating profits; EPS dropped 51.1% to KRW 1,328.
EBITDA increased 9.7% to KRW 421 billion, with a margin of 27.2%.
Tobacco segment sales rose 12.6% year-over-year to KRW 2,078.5 billion, maintaining a 68.4% share of total revenue.
Health functional foods sales declined 6.7% to KRW 535.0 billion, while real estate surged 94.3% to KRW 244.1 billion.
Outlook and guidance
Double-digit annual operating profit growth targeted for 2025, with continued momentum in global CC and improved cost competitiveness.
Guidance maintained due to ongoing uncertainties in FX rates, raw material prices, and geopolitical factors, but management aims to outperform double-digit operating profit.
The company plans to expand its online sales channels and further globalize its tobacco and health food businesses.
Ongoing investments in production capacity and ESG initiatives are expected to support long-term growth.
Management reaffirmed its commitment to shareholder returns, including a new share buyback and dividend policy.
Latest events from KT&G
- Record FY24 results with global growth, higher dividends, and aggressive buybacks.033780
Q4 202424 Jun 2026 - Q2 profit jumped on global tobacco gains, but 2024 outlook was cut as HFF and real estate lagged.033780
Q2 202424 Jun 2026 - Record tobacco growth and shareholder returns offset declines in net income and real estate.033780
Q3 202424 Jun 2026 - Q1 2025 revenue up 15.4% YoY, strong profit growth, and ongoing share buybacks.033780
Q1 202524 Jun 2026 - Record revenue and profit, net income up 73.4%, guidance raised, global expansion planned.033780
Q3 202524 Jun 2026 - Record Q1 revenue and profit growth driven by global tobacco and health foods, with stronger dividends ahead.033780
Q1 202622 Jun 2026 - 2025 saw record revenue, profit, and shareholder returns, led by global CC and real estate growth.033780
Q4 20255 Feb 2026 - Accelerated global growth, record shareholder returns, and new Altria partnership drive expansion.033780
Investor Day 2025 Presentation23 Sep 2025